High Scoring Large Cap stocks have outperformed low scoring stocks by 90% over last 4 years
Profitability: Recent profitability of 13% is a good sign.
Past Returns: In past three years, the stock has provided 15.4% return compared to 9.1% by NIFTY 50.
Smart Money: Smart money has been increasing their position in the stock.
Balance Sheet: Strong Balance Sheet.
Buy Backs: Company has bought back it's stock in the past which is a good thing.
Momentum: Stock price has a strong positive momentum. Stock is up 13.6% in last 30 days.
Size: It is among the top 200 market size companies of india.
No major cons observed.
Valuation | |
|---|---|
| Market Cap | 1.16 LCr |
| Price/Earnings (Trailing) | 29.81 |
| Price/Sales (Trailing) | 3.98 |
| EV/EBITDA | 17.71 |
| Price/Free Cashflow | 49.42 |
| MarketCap/EBT | 22.15 |
| Enterprise Value | 1.15 LCr |
Fundamentals | |
|---|---|
| Revenue (TTM) | 29.04 kCr |
| Rev. Growth (Yr) | -4.7% |
| Earnings (TTM) | 3.86 kCr |
| Earnings Growth (Yr) | -55.3% |
Profitability | |
|---|---|
| Operating Margin | 19% |
| EBT Margin | 18% |
| Return on Equity | 11.19% |
| Return on Assets | 9.09% |
| Free Cashflow Yield | 2.02% |
Growth & Returns | |
|---|---|
| Price Change 1W | 9.1% |
| Price Change 1M | 13.6% |
| Price Change 6M | -7.8% |
| Price Change 1Y | -5.5% |
| 3Y Cumulative Return | 15.4% |
| 5Y Cumulative Return | 8.8% |
| 7Y Cumulative Return | 14.1% |
| 10Y Cumulative Return | 10.8% |
Cash Flow & Liquidity | |
|---|---|
| Cash Flow from Investing (TTM) | -2.33 kCr |
| Cash Flow from Operations (TTM) | 3.94 kCr |
| Cash Flow from Financing (TTM) | -1.23 kCr |
| Cash & Equivalents | 1.02 kCr |
| Free Cash Flow (TTM) | 2.34 kCr |
| Free Cash Flow/Share (TTM) | 28.98 |
Balance Sheet | |
|---|---|
| Total Assets | 42.5 kCr |
| Total Liabilities | 7.98 kCr |
| Shareholder Equity | 34.52 kCr |
| Current Assets | 24.15 kCr |
| Current Liabilities | 7.01 kCr |
| Net PPE | 6.04 kCr |
| Inventory | 6.6 kCr |
| Goodwill | 3.75 kCr |
Capital Structure & Leverage | |
|---|---|
| Debt Ratio | 0.01 |
| Debt/Equity | 0.01 |
| Interest Coverage | 95.04 |
| Interest/Cashflow Ops | 73.44 |
Dividend & Shareholder Returns | |
|---|---|
| Dividend/Share (TTM) | 29 |
| Dividend Yield | 1.98% |
| Shares Dilution (1Y) | 0.00% |
| Shares Dilution (3Y) | 0.10% |
Profitability: Recent profitability of 13% is a good sign.
Past Returns: In past three years, the stock has provided 15.4% return compared to 9.1% by NIFTY 50.
Smart Money: Smart money has been increasing their position in the stock.
Balance Sheet: Strong Balance Sheet.
Buy Backs: Company has bought back it's stock in the past which is a good thing.
Momentum: Stock price has a strong positive momentum. Stock is up 13.6% in last 30 days.
Size: It is among the top 200 market size companies of india.
No major cons observed.
Investor Care | |
|---|---|
| Dividend Yield | 1.98% |
| Dividend/Share (TTM) | 29 |
| Shares Dilution (1Y) | 0.00% |
| Earnings/Share (TTM) | 48.04 |
Financial Health | |
|---|---|
| Current Ratio | 3.44 |
| Debt/Equity | 0.01 |
Technical Indicators | |
|---|---|
| RSI (14d) | 66.15 |
| RSI (5d) | 84.3 |
| RSI (21d) | 68.72 |
| MACD Signal | Buy |
| Stochastic Oscillator Signal | Sell |
| SharesGuru Signal | Buy |
| RSI Signal | Hold |
| RSI5 Signal | Sell |
| RSI21 Signal | Hold |
| SMA 5 Signal | Buy |
| SMA 10 Signal | Buy |
| SMA 20 Signal | Buy |
| SMA 50 Signal | Buy |
| SMA 100 Signal | Buy |
Summary of Cipla's latest earnings call, featuring management's outlook on business performance, financial results, and analyst Q&A sessions that highlight key strategic initiatives and market challenges.
In the Q4 FY26 earnings call for Cipla Limited, management provided an optimistic outlook for the future performance of the company across various divisions. Here are the key forward-looking points mentioned:
Revenue Projections: Management aims to achieve a run rate of $1 billion in North America by the end of FY27, driven by new product launches and increasing market demand. The expectation is to significantly increase quarterly revenues, projecting an average of about $100 million in incremental revenue in the second half of FY27.
Profitability Guidance: Cipla expects EBITDA margins in the range of 18.5% to 20% for FY27. This forecast takes into consideration ongoing investments in R&D and manpower, along with geopolitical challenges potentially impacting costs.
Expansion Plans: The company plans to introduce 17 new products in FY27, contributing to sustained growth in its One India business, which saw revenue surpass INR 12,500 crores. Management targets double-digit growth above the industry average in chronic therapies like diabetes, cardiology, and dermatology.
Strengthened Pipeline: Cipla has a strong pipeline, with nearly 40 to 50 product approvals expected over the next three years, including 12 first-to-file opportunities and 8 biosimilars. There is a focus on advanced therapies, including complex generics and respiratory products, which are expected to enhance margins.
Geographic Growth: The company anticipates continued robust performance in its One Africa and EMEU businesses, aiming for further penetration and cost optimization measures to navigate market volatility and maintain margins.
AI and Technology Investments: Management plans to leverage AI technology to improve operational efficiency and decision-making, which is expected to enhance productivity in R&D and manufacturing.
Overall, Cipla's strategic initiatives and focus areas indicate a commitment to driving growth and improving profitability across its diverse global markets.
1. Question: "During the quarter, did we kind of book any shelf stock adjustment for Revlimid?"
Answer: No, we did not have any shelf stock adjustments for Revlimid during this quarter. This aligns with what we communicated in the last quarter as well.
2. Question: "On the generic Ventolin launch expected next month, how would a switch to a newer variant from the innovator impact Cipla?"
Answer: The switch to a different variant is not automatic under U.S. law, so we do not anticipate any immediate impact on our sales from this transition.
3. Question: "Can you update on the respiratory pipeline, particularly Advair, Symbicort, and others?"
Answer: We've anticipated four approvals this year; Ventolin has been approved. We expect Advair and Symbicort among others to follow, with approvals likely in H1 and H2.
4. Question: "What is holding back Advair from being approved?"
Answer: The delay was due to an OAI classification at our Indore facility; however, we've since tech-transferred to the U.S. and are now prepared for the approval process.
5. Question: "What specific initiatives are you implementing around AI?"
Answer: We plan end-to-end implementations across various functions, focusing on quality and regulatory improvements, ultimately driving productivity and better decision-making.
6. Question: "What is Cipla's strategy for biosimilars?"
Answer: We're focusing on in-house development for biosimilars, aiming for 6 to 8 assets over the next 5 to 8 years, while considering limited in-licensing for immediate opportunities.
7. Question: "What is the U.S. revenue guidance of $1 billion by FY '27 based on?"
Answer: This is contingent on our pipeline maturing with several key approvals expected; we do not expect to achieve $1 billion in annual revenue but rather that exit run rate by year's end.
8. Question: "What is the outlook for Lanreotide?"
Answer: We're assisting our partner with remediation. We expect better clarity next quarter, aiming for approval of an alternate manufacturing site within the year.
9. Question: "How will the generic Ventolin product ramp up?"
Answer: While we'll launch in Q1, we expect a significant ramp-up in market share during the second half due to exclusivity and strong product demand.
10. Question: "What should be expected for gross margins with a more complex product pipeline?"
Answer: We expect a positive bias for gross margins moving forward. Chronic products typically have better margins, though geopolitical factors may introduce temporary fluctuations.
Analysis of Cipla's financial performance, highlighting revenue trends, growth patterns, and key metrics through quarterly analysis.
Last Updated: Dec 31, 2025
| Description | Share | Value |
|---|---|---|
| Pharmaceuticals | 94.6% | 6.7 kCr |
| New ventures | 5.4% | 381.5 Cr |
| Total | 7.1 kCr |
Understand Cipla ownership landscape with insights into key distribution patterns, offering investors a clear view of stakeholder dynamics.
| Shareholder Name | Holding % |
|---|---|
| Yusuf Khwaja Hameid | 18.69% |
| LICI NEW ENDOWMENT PLUS-SECURED FUND | 9.62% |
| SOPHIE AHMED | 5.71% |
| HDFC LARGE AND MID CAP FUND | 4.35% |
| M K HAMIED | 3.46% |
| SBI NIFTY 50 ETF | 2.96% |
| ICICI PRUDENTIAL PHARMAHEALTHCARE AND DIAGANOSTIC | 2.4% |
| DSP HEALTHCARE FUND | 1.78% |
| NPS TRUST A/C - LIC PENSION FUND - UPS - CG SCHEM | 1.69% |
| PARAG PARIKH FLEXI CAP FUND | 1.69% |
| NIPPON LIFE INDIA TRUSTEE LTD-A/C NIPPON INDIA ARB | 1.69% |
| Kamil Hamied | 1.36% |
| SAMINA HAMIED | 0% |
| RUMANA HAMIED | 0% |
| SHIRIN HAMIED | 0% |
| Farida Hamied | 0% |
| MN Rajkumar Garments LLP | 0% |
| Shree Riddhi Chemicals LLP | 0% |
| Alps Remedies Private Limited | 0% |
| Hamsons Laboratories LLP | 0% |
Distribution across major stakeholders
Distribution across major institutional holders
Detailed comparison of Cipla against industry peers, highlighting key financial metrics, valuation ratios, and performance indicators to provide competitive context within the sector.
Ticker | Name | Mkt Cap | Revenue | Price %, 1M | Returns, 1Y | P/E | P/S | Rev 1-Yr | Inc 1-Yr |
|---|---|---|---|---|---|---|---|---|---|
| SUNPHARMA | Sun Pharmaceutical Industries | 4.52 LCr | 58.94 kCr | +12.30% | +8.80% | 41.37 | 7.66 | - | - |
| DIVISLAB | Divi's Lab | 1.83 LCr | 10.75 kCr | +10.90% | +5.00% | 73.97 | 17.05 | - | - |
| DRREDDY | Dr. Reddy's Lab | 1.11 LCr | 35.06 kCr | +8.10% | +9.60% | 26.5 | 3.18 | - | - |
| LUPIN | Lupin | 1.05 LCr | 28.38 kCr | -1.70% | +12.70% | 19.59 | 3.68 | - | - |
| AUROPHARMA | Aurobindo Pharma | 87.82 kCr | 33.73 kCr | +9.10% | +25.40% | 25.18 | 2.6 | - | - |
Comprehensive comparison against sector averages
CIPLA metrics compared to Pharmaceuticals
| Category | CIPLA | Pharmaceuticals |
|---|---|---|
| PE | 29.81 | 36.98 |
| PS | 3.98 | 5.08 |
| Growth | 2.2 % | 9.8 % |
Cipla is a prominent pharmaceuticals company known for its extensive involvement in the manufacture, development, sale, and distribution of pharmaceutical products.
The company, with the stock ticker CIPLA, boasts a market capitalization of Rs. 125,567.8 Crores. Cipla operates not only in India but also in significant international markets like the United States and South Africa, making it a key player in the global pharmaceuticals landscape.
Cipla's operations are divided into two primary segments: Pharmaceuticals and New Ventures. The company offers a wide range of products including generic and branded generic medicines, vaccines, active pharmaceutical ingredients, and various formulations targeting a multitude of therapeutic areas. These areas encompass cardiovascular health, pulmonary diseases, neurological conditions, infectious diseases, oncology, diabetes, and more.
Additionally, Cipla is actively involved in consumer healthcare, biosimilars, and specialty businesses, highlighting its diverse portfolio. Founded in 1935 and headquartered in Mumbai, India, Cipla has established itself as a trusted name in the industry.
In financial terms, Cipla reported a trailing 12-month revenue of Rs. 27,802.9 Crores and recorded a profit of Rs. 4,986.9 Crores over the past four quarters. The company has witnessed a 30% growth in revenue over the past three years and offers a dividend yield of 0.88% per year, having distributed Rs. 13 per share in dividends in the past year. However, it is worth noting that Cipla has diluted its shareholders' holdings by 0.1% in the last three years.
This is an informational page just to provide a quick 'first look' at the stock. You must do your own deeper research. Know your risk appetite. Consult a SEBI-registered financial advisor before making any investment decisions.
CIPLA vs Pharmaceuticals (2021 - 2026)